Page last updated: 2024-11-07

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123683
CHEMBL ID119709
CHEBI ID73286
SCHEMBL ID465039
MeSH IDM0225644

Synonyms (75)

Synonym
cf101
MLS002153391
smr001230772
3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide
gtpl422
si-615
cf-101
ibmeca
rpr-113090
ib-meca, solid, >=98% (hplc)
ib-meca
NCGC00024978-03
NCGC00024978-04
cf 101
n(6)-ibamu
1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-beta-d-ribofuranuronamide
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
beta-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amo)-9h-purin-9-yl)-n-methyl-
n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
3-ib-meca
NCGC00024978-02
152918-18-8
NCGC00024978-05
(2s,3s,4r,5r)-3,4-dihydroxy-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
n6-(3-iodobenzyl)-5''-n-methylcarboxamidoadenosine
(2s,3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide
(2s,3s,4r,5r)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide
bdbm50118812
(n-6-(3-iodobenzyl)adenosine-5''-n-methyluronamide
(3s,4r,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide
(3r,4s,5r)-3,4-dihydroxy-5-[6-(3-iodo-benzylamino)-purin-9-yl]-tetrahydro-furan-2-carboxylic acid methylamide
chebi:73286 ,
CHEMBL119709 ,
(2s,3s,4r,5r)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-n-methyloxolane-2-carboxamide
HMS2234I04
n(6)-(3-iodo-benzyl)adenosine-5'-n-methyluronamide
3-iodobenzyl-5'-n-methylcarboxamidoadenosine
(2s,3s,4r,5r)-5-{6-[(3-iodobenzyl)amino]-9h-purin-9-yl}-3,4-dihydroxy-n-methyltetrahydrofuran-2-carboxamide
30679umi0n ,
piclidenoson [usan]
unii-30679umi0n
piclidenoson
DB05511
(2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
piclidenoson [inn]
piclidenoson [who-dd]
n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide
.beta.-d-ribofuranuronamide, 1-deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9h-purin-9-yl)-n-methyl-
CS-5048
REGID_FOR_CID_123683
SCHEMBL465039
1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-?-d-ribofuranuronamide
adenosine, n(6)-[3-iodobenzyl]-4'-methylcarbamoyl-4'-dehydroxymethyl-
HUJXGQILHAUCCV-MOROJQBDSA-N
(2s,3s,4r,5r)-3,4-dihydroxy-5-(6-((3-iodobenzyl)amino)-9h-purin-9-yl)-n-methyltetrahydrofuran-2-carboxamide
HY-13591
AKOS024456363
DTXSID50165158
1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide
D10971
piclidenoson (usan/inn)
J-008958
mfcd00671785
(2s,3s,4r,5r)-3,4-dihydroxy-5-(6-{[(3-iodophenyl)methyl]amino}-9h-purin-9-yl)-n-methyloxolane-2-carboxamide (non-preferred name)
EX-A2514
cf-101; ib-meca; piclidenoson
HMS3676E09
Q27088384
AS-16876
HMS3412E09
NCGC00024978-09
1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9h-purin-9-yl]-n-methyl-beta-d-ribofuranuronamide;n6-(3-iodobenzyl)adenosine-5'-n-methyluronamide;(2r,3r,4s,5s)-5-(6-(3-iodobenzylamino)-9h-purin-9-yl)-3,4-dihydroxy-n-methyl-tetrahydrofuran-2-carboxamide;cf 101
A848868
AC-36111
Q8L ,

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Sunitinib is an anti-cancer tyrosine kinase inhibitor associated with severe cardiotoxic adverse effects."( Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation.
Cooper, S; Hussain, A; Maddock, H; Mee, C; Sandhu, H, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" These pharmacokinetic parameters were linearly proportional to dose in the other treatment groups."( Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
Bar-Yehuda, S; Carey, WD; Clark, EV; Cohn, I; Fishman, P; Fong, KL; Kerns, WD; Silverman, MH; van Troostenburg, AR; Warrington, SJ, 2004
)
0.32
" We identify compounds with significantly improved bioactivity (approximately 40-fold) against replication of the infectious prion isoform (PrPSc) and suitable pharmacokinetic profiles to warrant evaluation in animal models of prion disease."( Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
Cohen, FE; Legname, G; May, BC; Prusiner, SB; Sherrill, J; Wallace, AC; Witkop, J; Zorn, JA, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" We conclude that the A3AR agonist CF101, a small orally bioavailable molecule, exerts systemic anticancer, antimetastatic, and myeloprotective effects in colon carcinoma-bearing mice, and may serve as an adjuvant treatment to enhance the chemotherapeutic index and prevent myelotoxicity."( Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Arich, A; Bar-Yehuda, S; Dreznick, Z; Fishman, P; Madi, L; Ohana, G; Rath-Wolfson, L; Silberman, D; Slosman, G, 2003
)
0.32
"CF101, an A3 adenosine receptor (A3AR) agonist, is a small orally bioavailable molecule known to suppress in vitro the production of tumor necrosis factor-alpha (TNF-alpha)."( Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
Baharav, E; Bar-Yehuda, S; Fishman, P; Halpren, M; Madi, L; Ochaion, A; Rath-Wolfson, L; Silberman, D; Weinberger, A, 2005
)
0.33
" IB-MECA, an orally bioavailable molecule, activates the A3AR, inducing receptor downregulation and the initiation of a molecular mechanism that involves de-regulation of the PI3K-NF-kappaB signaling pathway."( The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
Baharav, E; Bar-Yehuda, S; Cohen, S; Fishman, P; Madi, L; Ochaion, A; Rath-Wolfson, L, 2006
)
0.33
"IB-MECA, a small highly bioavailable molecule, induces modulation of proteins which control survival and apoptosis resulting in the amelioration of the inflammatory process and the preservation of bone mass in AIA rats."( IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.
Bar-Yehuda, S; Cohen, S; Fishman, P; Madi, L; Ochaion, A; Rath-Wolfson, L; Zabutti, A,
)
0.13
" Taken together, this information suggests that A(3)AR agonists may be a new family of orally bioavailable drugs to be developed as potent inhibitors of autoimmune-inflammatory diseases."( The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.
Bar-Yehuda, S; Cohen, S; Fishman, P; Kerns, WD; Ochaion, A; Silverman, MH, 2007
)
0.34
" CF101 is a highly specific orally bioavailable A3AR agonist."( Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Adawi, M; Caspi, D; Cohen, S; Cohn, I; Farbstein, M; Fishman, P; Fishman-Furman, S; Friedman, J; Green, L; Kerns, WD; Langevitz, P; Mader, R; Markovits, D; Molad, Y; Nahir, M; Ochaion, A; Reitblat, T; Rosner, I; Rozenbaum, M; Rubinow, A; Silverman, MH; Strand, V; Tanay, A; Tishler, M; Yehuda, SB, 2008
)
0.35
" CF101, an orally bioavailable A3AR agonist, has been analyzed in dry eye syndrome phase II clinical trials and was identified to be safe and well tolerated."( Targeting the A3 adenosine receptor for glaucoma treatment (review).
Bar-Yehuda, S; Cohen, S; Fishman, P, 2013
)
0.39
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic effect demonstrated in a Phase 2 clinical trial in psoriasis patients."( Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
Benea, V; Bristol, DR; Cohen, S; Cosgarea, MR; Cristodor, P; David, M; Demerdjieva, ZV; Farbstein, M; Fishman, P; Gheorghe, N; Giurcaneanu, C; Gospodinov, DK; Harpaz, Z; Hitova, MC; Horia, B; Hristakieva, E; Kadurina, MI; Mateev, GS; Michael, Z; Morariu, HS; Nica, C; Patel, RV; Purcaru, AI; Ramon, M; Rotaru, M; Rusinova, MV; Silverman, MH; Simionescu, O; Solovastru, LG; Tsingov, II; Yankova, RK, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" For comparison, dose-response functions were obtained from double-recombinant human embryonic kidney 293 cells expressing the human A3 receptor and a chimeric Galphaq-i3 protein, which was required to establish A3-mediated calcium signaling."( Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.
Bober, L; Caux, C; de Bouteiller, O; Deno, G; Du, XK; Fan, X; Fossetta, J; Jackson, J; Lundell, D; Lunn, C; Palmer, RK; Soudé-Bermejo, A, 2003
)
0.32
" However, the 5 mg multiple-dose group reported headache, drowsiness, hot flushes and dizziness on standing; this declined with dosing duration and was not dose-limiting in this study."( Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
Bar-Yehuda, S; Carey, WD; Clark, EV; Cohn, I; Fishman, P; Fong, KL; Kerns, WD; Silverman, MH; van Troostenburg, AR; Warrington, SJ, 2004
)
0.32
" Increases in heart rate and neutrophil count were reversible during multiple dosing and were not dose-limiting in the repeat dose study."( Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
Bar-Yehuda, S; Carey, WD; Clark, EV; Cohn, I; Fishman, P; Fong, KL; Kerns, WD; Silverman, MH; van Troostenburg, AR; Warrington, SJ, 2004
)
0.32
" Thus, the dosing and timing of IB-MECA treatment determines its effectivity in stimulating granulopoiesis under conditions of myelosuppression."( Effects of adenosine A(3) receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice.
Hofer, M; Holá, J; Pospísil, M; Streitová, D; Vacek, A; Weiterová, L; Znojil, V, 2006
)
0.33
" The most common adverse events were infections and gastrointestinal events, and there was no cumulative intolerance over the 32-week dosing period."( Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
Benea, V; Bristol, DR; Cohen, S; Cosgarea, MR; Cristodor, P; David, M; Demerdjieva, ZV; Farbstein, M; Fishman, P; Gheorghe, N; Giurcaneanu, C; Gospodinov, DK; Harpaz, Z; Hitova, MC; Horia, B; Hristakieva, E; Kadurina, MI; Mateev, GS; Michael, Z; Morariu, HS; Nica, C; Patel, RV; Purcaru, AI; Ramon, M; Rotaru, M; Rusinova, MV; Silverman, MH; Simionescu, O; Solovastru, LG; Tsingov, II; Yankova, RK, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
adenosine A3 receptor agonistAn agonist at the adenosine A3 receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
adenosinesAny purine ribonucleoside that is a derivative of adenosine.
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Purinergic signaling053

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
glp-1 receptor, partialHomo sapiens (human)Potency12.22390.01846.806014.1254AID624148; AID624172
ATAD5 protein, partialHomo sapiens (human)Potency5.10430.004110.890331.5287AID493106; AID493107; AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency20.98790.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency17.78280.00527.809829.0929AID588855
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency7.94333.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency28.18380.004611.374133.4983AID624297
relaxin receptor 1 isoform 1Homo sapiens (human)Potency15.84890.038814.350143.6206AID2676
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency16.94410.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
high affinity choline transporter 1 isoform aHomo sapiens (human)IC50 (µMol)2.10020.00036.210228.8403AID504840; AID588401
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)0.00170.00001.89408.5470AID1285610; AID1336302; AID1526077; AID1526078; AID1526081; AID1526082; AID1526083; AID1526084; AID1526085; AID1526087; AID1526088; AID1526089; AID1526090; AID1526094; AID255079; AID340233; AID346397; AID751701; AID751902
Adenosine receptor A3Homo sapiens (human)Ki0.05060.00000.930610.0000AID1179912; AID1280099; AID1282224; AID1312428; AID1408172; AID1443898; AID1451009; AID1674181; AID1725352; AID1819771; AID1819775; AID1819796; AID238913; AID239092; AID239235; AID239521; AID239561; AID254515; AID263889; AID263974; AID275293; AID32773; AID331881; AID33507; AID34574; AID346397; AID34721; AID34723; AID34875; AID391434; AID453374; AID453379; AID706384; AID751701; AID751902; AID763040; AID763041
Thyroid hormone receptor betaRattus norvegicus (Norway rat)Ki0.05400.00591.36889.0000AID32345
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.05400.00011.20929.9700AID32188; AID32345; AID32633; AID331882; AID706387
Adenosine receptor A1Bos taurus (cattle)Ki0.02260.00000.71316.0000AID239456; AID32002
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki10.00000.00000.385510.0000AID1324516
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki5.42000.00010.954910.0000AID1195795; AID1324466
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.00110.00030.91969.0000AID239053; AID331884; AID33337; AID33340; AID33341; AID33347; AID33351; AID33357; AID33485; AID33487; AID391436; AID706385
Adenosine receptor A2aHomo sapiens (human)Ki1.69260.00001.06099.7920AID1324471; AID1408170; AID1443897; AID1451011; AID238932; AID239113; AID239194; AID239329; AID239486; AID263970; AID331880; AID33928; AID34237; AID34238; AID34239; AID34242; AID391432; AID453377
Adenosine receptor A2bHomo sapiens (human)Ki6.52000.00021.635210.0000AID1408171; AID263972
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki0.05600.00061.353610.0000AID33569
Adenosine receptor A1Homo sapiens (human)Ki0.19080.00020.931610.0000AID1280098; AID1324468; AID1408169; AID1443896; AID1451010; AID238834; AID239011; AID239097; AID239280; AID263969; AID30451; AID30907; AID331879; AID391161; AID453375
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.05600.00021.494010.0000AID32878; AID331883; AID33569; AID33932; AID33939; AID33942; AID706389
Alpha-1A adrenergic receptorHomo sapiens (human)Ki0.05600.00000.272610.0000AID239194
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki1.08000.00030.769310.0000AID1195794; AID1324464
Beta-secretase 1Homo sapiens (human)Ki0.05400.00031.35248.0000AID238834
Adenylate cyclase type 5Rattus norvegicus (Norway rat)Ki0.00180.00140.04950.1180AID34574
Adenosine receptor A1Mus musculus (house mouse)Ki0.00590.00010.42424.4300AID331876
Adenosine receptor A2aMus musculus (house mouse)Ki1.00000.80803.199010.0000AID331877
Adenosine receptor A3Mus musculus (house mouse)Ki0.00010.00010.90956.3600AID331878
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)EC50 (µMol)0.00120.00010.42587.9800AID1573514; AID1573516; AID1573519; AID34265; AID34269
Adenosine receptor A2bHomo sapiens (human)EC50 (µMol)11.00000.00030.946110.0000AID33162
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)ED500.02800.02800.06400.1000AID263976
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (199)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (279)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID239456Displacement of [3H]DPCPX binding to adenosine A1 receptors of bovine cortical membranes2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID34574Affinity for human Adenosine A3 receptor expressed in CHO cell2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID1526077Agonist activity at wild type human A3 receptor stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID34269Inhibition of isoproterenol-stimulated cAMP accumulation in HEK 293 cells expressing human Adenosine A3 receptor2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
AID34238Binding affinity for HA-tagged mutant human Adenosine A2A receptor (V84L), using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID33569Binding affinity for A2-adenosine receptor by the displacement of specific [3H]-CGS- binding in rat striatal membranes was determined1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID1451011Displacement of [3H]CGS21680 from human A2A adenosine receptor expressed in HEK293 cell membranes after 60 mins by gamma counting method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1573538Ratio of pEC50 for agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as inhibition of forskolin-mediated cAMP accumulation to pEC50 for agonist activity at adenosine A3 receptor (unknown origin) expressed in serum starv2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID233279Selectivity for cloned rat A3 receptor1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID1526091Agonist activity at wild type human A3 receptor I268'7.39A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID453379Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.
AID1526081Agonist activity at wild type human A3 receptor V169'5.30A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID331888Selectivity for human adenosine A3 receptor over human adenosine A1 receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID239113Inhibition of [3H]-CGS- 21680 binding to human Adenosine A2A receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID229924Ratio of binding affinity for human adenosine A1 and A3 receptors2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
AID231119Ratio of binding affinities for A2 receptor compared to that of A3 receptor1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID1312428Binding affinity to human adenosine A3 receptor2016European journal of medicinal chemistry, Aug-08, Volume: 1181'-Homonucleosides and their structural analogues: A review.
AID1324467Displacement of [3H]mesulergine from human 5-HT2CR expressed in Flp-In HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1324464Displacement of [3H]lysergic from human 5-HT2BR expressed in HEK cell membranes incubated in dark for 90 mins by microbeta scintillation counting method
AID1443897Displacement of [3H]CGS21680 from human adenosine A2A receptor expressed in HEK293 cells after 60 mins by liquid scintillation analyzer
AID1451004Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in adiponectin production at 20.4 uM after 7 days in presence of IDX2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID32633Binding affinity against adenosine A1 receptor from rat brain.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID1451017Antidiabetic activity in STZ-induced diabetic C57BL/6J mouse assessed as insulin sensitivity by measuring reduction of serum lactate level at 20 mg/kg,po for 5 days2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1451034Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as adiponectin level at 20 uM measured on day 7 after 48 hrs by ELISA2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID263976Activity at adenosine A3 receptor expressed in HEK293 cells by inhibition of isoprotenol-stimulated cAMP gated channel2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID34272Percent efficacy against human Adenosine A3 receptor expressed in CHO cell2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID33485Tested for the binding affinity of A3 receptor by displacing N6-[[125I]-4-amino-3-iodobenzyl]-adenosine-5''-N-methyluronamide from membranes of CHO cells transfected with rat A3-cDNA1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID33939Tested for the binding affinity of A2a receptor by displacing the [3H]-CGS- 21680 in rat striatal membranes1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID263970Displacement of [125I]ZM241385 from human adenosine A2A receptor in HEK cells2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID1451008Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in number and size of lipid droplets at 20 uM after 7 days in presence of IDX by oil red O staining based inverted microscopic method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1526088Agonist activity at wild type human A3 receptor I253'6.58A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1526086Agonist activity at wild type human A3 receptor L246'6.51A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID239561Binding affinity towards human Adenosine A3 receptor stably transfected in CHO cells was determined using [125I]I-AB-MECA (1.0 nM) as radioligand2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor.
AID331882Displacement of radioligand from rat adenosine A1 receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID33208Agonist elicited inhibition of adenylyl cyclase via rat Adenosine A3 receptor in transfected CHO cells and effect on IB-MECA was determined from dose response curves at the concentration of 100(uM); No antagonism1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID234275Selectivity, ratio between A2A receptor binding affinity / A3 receptor binding affinity1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.
AID1408170Displacement of [3H]NECA from human adenosine A2A receptor expressed in CHO cell membranes after 3 hrs by micro beta scintillation counting method2018European journal of medicinal chemistry, Sep-05, Volume: 157[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
AID1451013Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARdelta LBD at 4 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1451025Inhibition of human CDK5/p25 up to 20 uM using histone H1 as substrate after 40 mins in presence of [gamma32P]ATP by scintillation counting2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID32024Binding affinity against adenosine A1 receptor in rat brain membranes using [3H]R-PIA.1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
AID32349Displacement of [3H]CHA from Adenosine A1 receptor in rat brain homogenates1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.
AID340233Inhibition of human adenosine A3 receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1443898Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells after 60 mins by gamma counting analysis
AID346397Displacement of radiolabeled IB-MECA from human adenosine A3 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID238834Displacement of [3H]CCPA from recombinant human adenosine A1 receptor expressed in CHO cells2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.
AID331887Selectivity for mouse adenosine A3 receptor over mouse adenosine A1 receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1195764Antinociceptive activity in chronic constriction injury neutropathic pain CD-1 mouse model assessed as time for peak protection at 3 umol/kg, po2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
AID32188Binding affinity for adenosine A1 receptor as displacement of [3H]R-PIA from rat brain membranes at 10e-4 M1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
AID1282224Binding affinity to Adenosine receptor A3 (unknown origin)2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
AID33341Binding affinity for rat A3-adenosine receptor expressed in chinese hamster ovarian cells (assayed by the displacement of specific [125I]-N6-(4-amino-3-iodobenzyl)-adenosine-5''-N-methyluronamide)1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID184414Inhibition of [3H]S-(4-Nitrobenzyl)-6-thioinosine binding to adenosine uptake sites in rat brain membranes1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID331884Displacement of radioligand from rat A3 adenosine receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1451019Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARalpha LBD at 20 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1451026Inhibition of human CDK5/p35 up to 20 uM using histone H1 as substrate after 40 mins in presence of [gamma32P]ATP by scintillation counting2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID453375Displacement of [3H]R-PIA from human adenosine A1 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.
AID230961Ratio of the concentration effecting adenylyl cyclase and binding affinity against rat brain A3 receptors.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID32021Binding affinity for A1-adenosine receptor by the displacement of specific [3H]-PIA binding in rat brain was determined1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID33162Effective concentration for cAMP production in CHO-KI cells stably transfected with human adenosine A2B receptor cDNA1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID1526087Agonist activity at wild type human A3 receptor I249'6.54A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID460067Agonist activity at human recombinant adenosine A3 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP release at 10 uM by liquid scintillation spectrophotometry relative to NECA2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.
AID1324459Displacement of [3H]LSD from human 5-HT6 receptor expressed in HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1451009Displacement of [125I]I-AB-MECA from human A3 adenosine receptor expressed in CHO cell membranes after 60 mins by gamma counting method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID706389Displacement of [3H]CGS21680 from rat adenosine A2A receptor expressed in CHO cells after 60 mins by gamma counter2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID32513Tested for the binding affinity of A1 receptor by displacing the [3H]-PIA in rat brain membranes1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID479322Cardioprotective effect against hypoxic simulated ischemia in rat H9c2 cells assessed as reduction in cell death at 10 nM after 12 hrs by propidium iodide staining-based inverted microscopy2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.
AID1451029Transactivation of human GST-tagged PPARdelta LBD assessed as fluorescein-C33 coactivator recruitment at 10 uM by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID33357Displacement of [125I]AB-MECA from cloned rat Adenosine A3 receptor in stably transfected CHO cells1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.
AID34721Binding affinity towards Adenosine A3 receptor (W243A)2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID263969Displacement of [125I]ABA from human adenosine A1 receptor expressed in HEK cells2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID1451018Antidiabetic activity in STZ-induced diabetic C57BL/6J mouse assessed as insulin sensitivity by measuring reduction of serum glucose levels at 20 mg/kg,po for 5 days measured at 1 and 4 hrs post last dose2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID238932Displacement of [3H]CGS-21680 from recombinant human adenosine A2a receptor expressed in HEK cells2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID32773Binding affinity using [125I]ABA against human Adenosine A3 receptor2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
AID1324457Displacement of [3H]5-HT from human 5-HT1E receptor expressed in HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID479321Cardioprotective effect against hypoxic simulated ischemia in rat H9c2 cells assessed as reduction in cell death at 100 nM after 12 hrs by propidium iodide staining-based inverted microscopy2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.
AID275291Inhibitory constant aganist human adenosine A1 receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID30451Binding affinity for human adenosine A1 receptor1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID453381Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as inhibition of cAMP accumulation2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.
AID1819771Displacement of [3H]HMRS7799 from human adenosine A3 receptor expressed in HEK293 cells by radioligand binding assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Selective A
AID1336302Displacement of [125I]AB-MECA from human recombinant adenosine receptor A3 expressed in HEK293 cells measured after 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID230967Ratio of the concentration (0.1 uM) effecting adenylyl cyclase and binding affinity against rat brain A3 receptors1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID1324516Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
AID263889Binding affinity to human adenosine A3 receptor2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor.
AID1443901Agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as decrease in forskolin induced cAMP formation preincubated for 10 mins followed by forskolin challenge measured after 15 mins by AlphaScreen assay relative to adenosine-5'-N
AID1674181Binding affinity to A3 receptor (unknown origin)2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
AID33323Ability to inhibit the adenylyl cyclase in CHO cells stably transfected with rat Adenosine A3 receptor at the concentration of 100 uM1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID239194Displacement of [3H]CGS-21680 binding to Adenosine A2 receptor expressed in CHO cells2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
AID706384Displacement of [125I]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells after 60 mins by gamma counter2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID239235Displacement of [125I]AB-MECA binding to Adenosine A3 receptor expressed in CHO cells2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
AID1285610Displacement of [125I]ABMECA from human recombinant adenosine A3 receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID1324468Displacement of [3H]N6-phenylisopropyladenosine from recombinant human A1AR expressed in CHO cell membranes after 60 mins by liquid scintillation counting method
AID239011Inhibition of [3H]R-PIA binding to human Adenosine A1 receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID1573514Agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as increase in ERK1/2 phosphorylation after 5 mins by alphascreen assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID255079Inhibitory concentration against human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID239097Displacement of [3H]CHA binding to Adenosine A1 receptor expressed in CHO cells2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
AID1451038Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARalpha LBD at 4 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID453374Binding affinity to human adenosine A3 receptor2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.
AID1408171Antagonist activity at human adenosine A2B receptor expressed in CHO cell membranes assessed as inhibition of NECA-stimulated adenylyl cyclase activity by [alpha-32P]ATP based assay2018European journal of medicinal chemistry, Sep-05, Volume: 157[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
AID33351Binding affinity for rat Adenosine A3 receptor in CHO cells using [125I]iodo-AB-MECA 2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.
AID32890Ability to displace radioligand [3H]- CGS 21680 from adenosine A2A receptor on rat striatal membrane1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID239280Binding affinity towards recombinant human Adenosine A1 receptor was determined using [3H]R-PIA (2.0 nM) as radioligand2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor.
AID34242Binding affinity for human adenosine A2A receptor1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID1573516Agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as inhibition of forskolin-mediated cAMP accumulation preincubated for 10 mins followed by forskolin addition measured after 30 mins by alphascreen assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID33928Inhibitory activity at Adenosine A2A receptor by inhibition of [3H]-CGS- 21680 binding to bovine striatal membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID453377Displacement of [3H]CGS21680 from human adenosine A2A receptor expressed in CHO cells2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.
AID331879Displacement of radioligand from human adenosine A1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID331881Displacement of radioligand from human adenosine A3 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID763040Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells after 90 mins by gamma counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1526092Agonist activity at wild type human A3 receptor S271'7.42A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID239521Displacement of [125I]AB-MECA from adenosine A3 receptors in bovine cortical membranes2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID1324456Displacement of [3H]5-CT from human 5-HT1D receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID33337Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID1195795Binding affinity to 5HT2C receptor (unknown origin) by PDSP screening2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
AID391434Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.
AID34265Effect on forskolin-stimulated cyclic AMP production in intact chinese hamster ovary (CHO) cell expressing the human Adenosine A3 receptor2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID1526083Agonist activity at wild type human A3 receptor M174'5.35A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID243075Ratio of binding affinity for Adenosine A1 and Adenosine A3 receptors2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
AID32878Binding affinity for adenosine A2A receptor as displacement of [3H]-CGS- 21680 from rat striatal membranes at 10e-4 M1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
AID1526089Agonist activity at wild type human A3 receptor I253'6.58E mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1324461Displacement of [3H]GR65630 from human 5-HT3 receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1526093Agonist activity at wild type human A3 receptor H272'7.43A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1526084Agonist activity at wild type human A3 receptor M177'5.38A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID32345Ability to displace radioligand [3H]- DPCPX from adenosine A1 receptor on rat cortical membrane in the absence of GTP1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID1324462Displacement of [3H]LSD from human 5-HT5A receptor expressed in Flp-In-CHO cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1573519Agonist activity at adenosine A3 receptor (unknown origin) expressed in serum starved CHO cells assessed as increase in cell survival after 24 hrs by propidium iodide staining-based assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID243039Relative affinities for adenosine A2A and A3 receptors (ratio of KiA2A/KiA3)2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID239053Inhibition of [125I]AB-MECA binding to rat Adenosine A3 receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID34239Binding affinity for HA-tagged wild type human Adenosine A2A receptor (WT) using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID479323Cardioprotective effect against hypoxic simulated ischemia in rat H9c2 cells assessed as reduction in cell death at 100 nM after 12 hrs by propidium iodide staining-based inverted microscopy in presence of adenosine A3 receptor antagonist MRS-11912010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.
AID33211Ability to inhibit the adenylyl cyclase in CHO cells stably transfected with rat Adenosine A3 receptor at the concentration of 0.1(uM)1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID751701Displacement of [3H]ABMECA from human recombinant adenosine receptor A3 expressed in CHOK1 cells after 60 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID331878Displacement of [125I]N6-(-amino-3-iodobenzyl)adenosine-5'-N-methyl-uronamide from mouse recombinant adenosine A3 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1819775Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in HEK293 cells by radioligand binding assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Selective A
AID1324460Displacement of [3H]LSD from human 5-HT7A receptor expressed in HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID233379Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 2A receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1451010Displacement of [3H]CCPA from human A1 receptor expressed in CHO cell membranes after 60 mins by gamma counting method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID239329Binding affinity towards recombinant human Adenosine A2a receptor was determined using [3H]CGS-21680 (10 nM) as radioligand2004Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19
Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor.
AID391432Displacement of [3H]CGS-21680 from human adenosine A2A receptor expressed in HEK293 cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.
AID32002Inhibitory activity at Adenosine A1 receptor by inhibition of [3H]CHA binding to bovine brain cortical membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1526079Agonist activity at wild type human A3 receptor T94'3.36A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1451027Transactivation of human PPARgamma expressed in African green monkey CV1 cells at 10 uM by luciferase reporter gene assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID230930Ratio of the binding affinities against rat brain A1 and A3 receptors, KiA1/KiA3.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID34875Displacement of [125I]AB-MECA from membranes of HEK 293 cells expressing human Adenosine A3 receptor1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID1195766Antinociceptive activity in chronic constriction injury neutropathic pain CD-1 mouse model at 3 umol/kg, po after 3 hrs post dose relative to control2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
AID1280099Binding affinity to adenosine A3 receptor (unknown origin)2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID32864Binding affinity against adenosine A2A receptor in rat striatal membranes using [3H]-CGS- 21680.1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
AID33206Agonist elicited inhibition of adenylyl cyclase via rat Adenosine A3 receptor in transfected CHO cells and effect on IB-MECA was determined from dose response curves at the concentration of 0.1(uM); No antagonism1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID1573520Agonist activity at adenosine A3 receptor (unknown origin) expressed in serum starved CHO cells assessed as increase in cell survival after 24 hrs by propidium iodide staining-based assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1443896Displacement of [3H]R-PLA from human adenosine A1 receptor expressed in CHO cells after 60 mins by liquid scintillation analyzer
AID1573517Agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as inhibition of forskolin-mediated cAMP accumulation preincubated for 10 mins followed by forskolin addition measured after 30 mins by alphascreen assay relative to con2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1324454Displacement of [3H]WAY100635 from human 5-HT1AR expressed in CHO cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1451023Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARdelta LBD at 20 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1280098Binding affinity to adenosine A1 receptor (unknown origin)2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID1324465Displacement of [3H]lysergic from human 5-HT2BR expressed in HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID1526085Agonist activity at wild type human A3 receptor W185'5.46A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1179912Binding affinity to A3AR (unknown origin)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and evaluation of N⁶-substituted apioadenosines as potential adenosine A₃ receptor modulators.
AID1195794Binding affinity to 5HT2B receptor (unknown origin) by PDSP screening2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
AID1451035Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as adiponectin level at 4 uM measured on day 7 after 48 hrs by ELISA2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID706385Displacement of [125I]I-AB-MECA from human rat adenosine A3 receptor expressed in CHO cells after 60 mins by gamma counter2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID33482Inhibitory activity against Adenosine A3 receptor by inhibiting specific [3H](R)-PIA binding to rat testis membranes1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1451005Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in the production of adiponectin measured on day 7 after 48 hrs by ELISA2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID33347Binding affinity for rat adenosine A3 receptor1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
AID1526082Agonist activity at wild type human A3 receptor V169'5.30E mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1451016Antidiabetic activity in STZ-induced diabetic C57BL/6J mouse assessed as insulin sensitivity by measuring reduction of serum triglyceride level at 20 mg/kg,po for 5 days2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID331876Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5'-N-methyl-uronamide from mouse recombinant adenosine A1 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID706383Selectivity ratio of Ki for rat adenosine A1 receptor to Ki for rat adenosine A3 receptor expressed in CHO cells2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID1324466Displacement of [3H]mesulergine from human 5-HT2CR expressed in Flp-In HEK cell membranes incubated for 90 mins under dark condition by microbeta scintillation counting method
AID263972Displacement of [125I]ABOPX from human adenosine A2B receptor in HEK cells2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID233377Inhibitory selectivity at Adenosine 2A receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID232045Selectivity for binding affinity towards A2A adenosine receptor in rat striatal membrane and rat A3 receptor expressed in CHO cells.1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
AID1408172Displacement of [3H]HEMADO from human adenosine A3 receptor expressed in CHO cell membranes after 3 hrs by micro beta scintillation counting method2018European journal of medicinal chemistry, Sep-05, Volume: 157[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
AID239092Inhibition of [125I]-AB-MECA binding to human Adenosine A3 receptor expressed in CHO cells2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID33052Binding affinity towards Adenosine A3 receptor (H95A receptor); Not determined2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID1195765Antinociceptive activity in chronic constriction injury neutropathic pain CD-1 mouse model assessed as maximum protection on ipsilateral hind paw at 3 umol/kg, po after 30 mins to 5 hrs post dose relative to control2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
AID33487Binding affinity against adenosine A3 receptor from rat brain.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID263974Displacement of [125I]ABA from human adenosine A3 receptor expressed in HEK cells2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID391436Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.
AID1451037Antagonist activity at human GST-tagged PPARalpha LBD assessed as reduction in GW501516-induced fluorescein-C33 coactivator recruitment at 1 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID751902Binding affinity to human adenosine A3 receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID1650493Binding affinity to GST-tagged human PPARalpha LBD up to 30 uM incubated for 2 to 6 hrs by TR-FRET assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
AID232044Selectivity for binding affinity towards A1 adenosine receptor in rat brain membrane and rat A3 receptor expressed in CHO cells.1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
AID1526094Agonist activity at wild type human A3 receptor V169'5.30A/W185'5.46A double mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID391161Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.
AID1451021Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARgamma LBD at 20 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID34237Binding affinity for HA-tagged mutant human Adenosine A2A receptor (H250N) using [3H]-CGS-21,680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID331877Displacement of [3H]2-[p-(2-carboxyethyl)phenyl-ethylamino]-5'-N-ethylcarboxamidoadenosine from mouse recombinant adenosine A2A receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1324455Displacement of [3H]5-CT from human 5-HT1BR expressed in HEK cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID33932Displacement of [3H]-CGS- 21680 from Adenosine A2A receptor in rat striatal homogenates1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.
AID275293Inhibitory constant against human adenosine A3 receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID229821Ratio of Ki for A1 and A3 receptors1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID1451002Binding affinity to human LXRbeta at 4 uM by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID706381Selectivity ratio of Ki for rat adenosine A2A receptor to Ki for rat adenosine A3 receptor expressed in CHO cells2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID1408169Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cell membranes after 3 hrs by micro beta scintillation counting method2018European journal of medicinal chemistry, Sep-05, Volume: 157[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
AID233378Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID751766Displacement of [3H]ABMECA from human recombinant adenosine receptor A3 expressed in CHOK1 cells at 10 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1725352Binding affinity to human A3AR assessed as inhibitor constant
AID331889Selectivity for rat adenosine A3 receptor over rat adenosine A1 receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1819796Binding affinity to human adenosine A3 receptor measured by radioligand binding assay2022ACS medicinal chemistry letters, Apr-14, Volume: 13, Issue:4
Selective A
AID275292Inhibitory constant against human adenosine A2a receptor2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID1573515Agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as increase in ERK1/2 phosphorylation after 5 mins by alphascreen assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID238913Displacement of [125I]-AB MECA from recombinant human adenosine A3 receptor expressed in HEK cells2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.
AID33942Binding affinity against adenosine A2A receptor from rat brain.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID1526080Agonist activity at wild type human A3 receptor F168'5.29A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID34723Displacement of [125I]AB-MECA from adenosine A3 receptor from HEK293 cell membranes1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
AID33340Binding affinity against rat adenosine A3 receptor expressed in CHO cells using [125I]-.1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
AID331883Displacement of radioligand from rat adenosine A2A receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1526076Agonist activity at wild type human A3 receptor N250'6.55A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID331880Displacement of radioligand from human adenosine A2A receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID243038Relative affinities against adenosine A2A and A1 receptors (ratio of KiA2A/KiA1)2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID1451024Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARdelta LBD by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID251590Relative activation of human Adenosine A3 receptor expressed in CHO cells at 10 uM treatment compared to 10 uM Cl-IB-MECA2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID275284Reduction of PrPSC accumulation in ScN2a cells2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.
AID239486Displacement of [3H]CGS-21680 binding to adenosine A2A receptors of bovine striatal membranes2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID230000Ratio of Ki for A2a and A3 receptors1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.
AID263975Selectivity for human adenosine A3 receptor over human adenosine A1 receptor2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
AID231118Ratio of binding affinities for A1 receptor compared to that of A3 receptor1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID230931Ratio of the binding affinities against rat brain A2a and A3 receptors, KiA2a/KiA3.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
AID1526078Agonist activity at wild type human A3 receptor L90'3.32A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID263890Selectivity for human adenosine A3 receptor over human adenosine A1 receptor2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor.
AID243033Relative affinities for adenosine A3 and A1 receptors (ratio of KiA3/KiA1)2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID1324458Displacement of [3H]GR113808 from human 5-HT4 receptor at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID251589Relative activation of human Adenosine A2B receptor at 10 uM treatment compared to 10 uM Cl-IB-MECA2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID234274Selectivity, ratio between A1 receptor binding affinity / A3 receptor binding affinity1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.
AID1526090Agonist activity at wild type human A3 receptor L264'7.35A mutant stably expressed in Flp-In CHO cells cotransfected with pOG44 assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by LANCE assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structural Characterization of Agonist Binding to an A
AID1451006Binding affinity to human LXRalpha at 4 uM by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1451014Displacement of Fluormone-GS1 from human GST-tagged glucocorticoid receptor LBD at 4 uM by TR-FRET assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1324471Displacement of [3 H]2-[p-(2-carboxyethyl)phenyl-ethylamino]-5'-N-ethylcarboxamidoadenosine from recombinant human adenosine receptor A2A expressed in HEK293 cell membranes after 60 mins by liquid scintillation counting method
AID1324463Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-T cell membranes at 10 uM incubated for 90 mins under dark condition by microbeta scintillation counting method relative to control
AID706387Displacement of [3H]CCPA from rat adenosine A1 receptor expressed in CHO cells after 60 mins by gamma counter2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID30907Binding affinity using [125I]ABA against human Adenosine A1 receptor2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
AID763041Competitive binding affinity to human adenosine A3 receptor expressed in CHO cells after 90 mins by flow cytometric analysis in presence of MRS54492013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID331892Activation of mouse adenosine A2B receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
AID1573518Ratio of pEC50 EC50 for agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells assessed as inhibition of forskolin-mediated cAMP accumulation to pEC50 for agonist activity at human adenosine A3 receptor expressed in FlpIn-CHO cells a2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID33507Binding affinity towards human Adenosine A3 receptor wild type2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
AID254515Binding affinity towards human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1345618Human A2A receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345618Human A2A receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345685Human A1 receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345822Human A3 receptor (Adenosine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
AID1345822Human A3 receptor (Adenosine receptors)1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.
AID1345721Human A2B receptor (Adenosine receptors)1999Molecular pharmacology, Oct, Volume: 56, Issue:4
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
AID1345822Human A3 receptor (Adenosine receptors)2000Molecular pharmacology, May, Volume: 57, Issue:5
[(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
AID1345618Human A2A receptor (Adenosine receptors)1995The Journal of biological chemistry, Jun-09, Volume: 270, Issue:23
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor.
AID1345822Human A3 receptor (Adenosine receptors)2001Biochemical pharmacology, Nov-01, Volume: 62, Issue:9
Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2).
AID1345721Human A2B receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (210)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's39 (18.57)18.2507
2000's97 (46.19)29.6817
2010's62 (29.52)24.3611
2020's12 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.22 (24.57)
Research Supply Index5.39 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (2.34%)5.53%
Reviews16 (7.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other193 (90.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]